Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 16/20 | 0.74 |
| ▸ | PRKCA | P17252 | 2/20 | 0.58 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.54 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.54 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.51 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6576948 | 1.00 | CDK1 (0.74) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6578314 | 0.93 | CDK1 (0.69) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6578317 | 0.93 | CDK1 (0.69) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6576122 | 0.91 | CDK1 (0.77) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6576120 | 0.91 | CDK1 (0.77) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6576100 | 0.87 | CDK1 (0.69) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6576095 | 0.87 | CDK1 (0.69) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL5840235 | 0.85 | CDK1 (1.00) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL5840229 | 0.85 | CDK1 (1.00) | CDK1PRKCACCNB2CCNB1CCNB3 | |
| SCHEMBL6574902 | 0.85 | CDK1 (0.71) | CDK1PRKCACCNB2CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767906-B2 | INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. | NOVARTIS AG (CH) | 2004-07-27 | — | — | US | claimed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | claimed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |